Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA grants Brukinsa accelerated approval in relapsed or refractory marginal zone lymphoma – BeiGene

Written by | 2 Feb 2022

BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL)… read more.

Robot performs first laparoscopic surgery without human help

Written by | 2 Feb 2022

A robot has performed laparoscopic surgery on the soft tissue of a pig without the guiding hand of a human — a significant step in robotics toward fully… read more.

EMPEROR-Preserved phase III trial of Jardiance shows efficacy in heart failure – Eli Lilly + Boehringer

Written by | 1 Feb 2022

Jardiance (empagliflozin), from Eli Lilly and Boehringer, reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline… read more.

Stroke higher among young women than men

Written by | 1 Feb 2022

The incidence of stroke incidence appears to be greater in women under 35 years-old than in men of the same age group, researchers reported on Jan. 24, 2022… read more.

Update on the phase IV confirmatory study of Aduhelm for Alzheimer’s disease – Biogen + Eisai

Written by | 31 Jan 2022

Biogen Inc. and Eisai Co., Ltd. provided an important update on the continuing progress of the Phase IV post-marketing confirmatory study of Aduhelm (aducanumab-avwa) 100 mg/mL injection for… read more.

Farther or faster? Both improve distance running performance

Written by | 31 Jan 2022

A study performed at the University of Jyväskylä compared two-week blocks of low-intensity training and high-intensity interval training in terms of performance and recovery. Both methods can improve… read more.

AbbVie provides update on Rinvoq for the treatment of rheumatoid arthritis in the U.S

Written by | 30 Jan 2022

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This… read more.

Current anti-COVID pills work well against omicron, but antibody drugs are less effective, study finds

Written by | 30 Jan 2022

The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study. However,… read more.

European Commission approves Lenvima + Keytruda to treat endometrial carcinoma – Eisai + Merck Inc.

Written by | 29 Jan 2022

Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.

Rural air pollution may be as hazardous as urban, study finds

Written by | 29 Jan 2022

New research shows that chemical reactivity, seasonality and distribution of airborne particulate matter are critical metrics when considering air pollution’s impact on human health. Current environmental regulations focus… read more.

Nanoparticle-formulated drug combination is effective in medulloblastoma, a pediatric brain tumor

Written by | 28 Jan 2022

UNC Lineberger Comprehensive Cancer Center researchers have demonstrated that a novel combination of two drugs that act as targeted inhibitors, delivered in a nanoparticle formulation, extend the survival… read more.

Cause, develop pharmacological treatment for reducing retinitis pigmentosa vision loss

Written by | 28 Jan 2022

Inhibiting ceramide accumulation in retina protects photoreceptors, improves vision. Researchers from the University of California, Irvine have discovered that the absence of Adiponectin receptor 1 protein (AdipoR1), one… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.